Evidence map›Paper›PMID 39574840›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Personalized azithromycin treatment rules for children with watery diarrhea using machine learning.

Sara S Kim, Allison Codi, James A Platts-Mills, Patricia Pavlinac, Karim Manji, Chris Sudfeld, Christopher P Duggan, Queen Dube, Naor Bar-Zeev, Karen Kotloff and 9 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Sara S KimDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0002-1056-9896
Allison CodiDepartment of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.ORCID 0000-0001-6562-607X
James A Platts-MillsDivision of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Patricia PavlinacDepartment of Global Health, University of Washington, Seattle, WA, USA.
Karim ManjiDepartment of Pediatrics and Child Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Chris SudfeldDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Christopher P DugganDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Queen DubeDepartment of Pediatrics, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Naor Bar-ZeevInternational Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, ML, USA.
Karen KotloffDepartment of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore.
Samba O SowCentre pour le Développement des Vaccins, Bamako, Mali.
Sunil SazawalCenter for Public Health Kinetics, New Delhi, Delhi, India.
Benson O SingaChildhood Acute Illness and Nutrition Network, Nairobi, Kenya.
Judd WalsonChildhood Acute Illness and Nutrition Network, Nairobi, Kenya.
Farah QamarDepartment of Pediatrics and Child Heath, Aga Khan University, Karachi, Pakistan.
Tahmeed AhmedNutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
Ayesha De CostaDepartment of Maternal, Child, and Adolescent Health and Aging, World Health Organization, Geneva, Switzerland.
David BenkeserDepartment of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Elizabeth T Rogawski McQuadeDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Funding

Targeted antibiotic therapy for Shigella among children in low-resource settingsR01AI185140 · NIAID · EMORY UNIVERSITY · PI Elizabeth Tacket Rogawski McQuade · 2024 to 2026
$2.2M
NIAID NIH HHS R01 AI185140
6 · The paper itself

Abstract

Introduction: We used machine learning to identify novel strategies to target azithromycin to the children with watery diarrhea who are most likely to benefit. Methods: Using data from a randomized trial of azithromycin for watery diarrhea, we developed personalized treatment rules given sets of diagnostic, child, and clinical characteristics, employing a robust ensemble machine learning-based procedure. For each rule, we estimated the proportion treated under the rule and the average benefits of treatment. Results: Among 6,692 children, treatment was recommended on average for approximately one third of children. The risk of diarrhea on day 3 was 10.1% lower (95% CI: 5.4, 14.9) with azithromycin compared to placebo among children recommended for treatment. For day 90 re-hospitalization and death, risk was 2.4% lower (95% CI: 0.6, 4.1) with azithromycin compared to placebo among those recommended for treatment. While pathogen diagnostics were strong determinants of azithromycin effects on diarrhea duration, host characteristics were more relevant for predicting benefits for re-hospitalization or death. Conclusion: The ability of host characteristics to predict which children benefit from azithromycin with respect to the most severe outcomes suggests appropriate targeting of antibiotic treatment among children with watery diarrhea may be possible without access to pathogen diagnostics.

Identifiers

PMID39574840
PMCPMC11581062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.